EFFECTIVENESS OF THE USE OF CERTOLIZUMAB PEGOL IN PATIENTS WITH PSORIASIS: SYSTEMATIC REVIEW

Abstract

Psoriasis is a very recurrent dermatological disease and can be treated with tumor necrosis factor alpha (TNFi) inhibitors. Among these drugs, we highlight Certolizumab Pegol for the treatment of patients with psoriasis. Considering the importance of this treatment, the present study aimed to evaluate the effectiveness of Certolizumab Pegol, an inhibitor of tumor necrosis factor alpha (TNFi), in patients with psoriasis. The method used was an integrative review of studies available on the Virtual Health Library (VHL), Pubmed and SciELO platform, over a period of 5 years, between 2018 and 2023, in English and Portuguese, and the Rayyan platform was used. The words "Psoríase" OR "Psoríase Pustular de Palmas e Plantas dos Pés” OR “Pustulose de Palmas e Plantas dos Pés” OR “Pustulose Palmoplantar” AND “Certolizumab pegol” OR “Cetolizumabe Pegol” OR “Cimzia” were used as descriptors. study used the PICO strategy to develop the guiding question that delimited the development of the research: “How effective is the use of Certolizumab pegol in patients with psoriasis?” After applying the inclusion criteria, no study from the BVS platform was selected, of the 20 found, in PUBMED of the 581 results found, only 02 were selected and on the SCIELO platform 02 results were found, none of which were selected for analysis. Through the evaluation of each selected article, the conclusion is that Certolizumab Pegol presents a positive effectiveness for patients with psoriasis, due to improvements in work productivity, however there are other medications that are safer and more effective for patients with psoriatic arthritis.